Merus Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merus stock.
View analyst ratings for Merus or view top-rated stocks.

Wall Street analysts have given Merus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Merus is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Merus.

Merus (NASDAQ:MRUS) posted its quarterly earnings data on Monday, March, 15th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.53. Merus had a negative net margin of 295.98% and a negative trailing twelve-month return on equity of 78.70%.
View Merus' earnings history.

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRUS stock has increased by 57.0% and is now trading at $22.83.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 1-year price objectives for Merus' shares. Their forecasts range from $21.00 to $33.00. On average, they expect Merus' stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts' price targets for Merus or view top-rated stocks among Wall Street analysts.

Some companies that are related to Merus include I-Mab (IMAB), Nektar Therapeutics (NKTR), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), ChemoCentryx (CCXI), Insmed (INSM), InnovAge (INNV), Reata Pharmaceuticals (RETA), Karuna Therapeutics (KRTX), Alkermes (ALKS), Pacira BioSciences (PCRX), Arvinas (ARVN), Organogenesis (ORGO) and MorphoSys (MOR).
View all of MRUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC).

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRUS stock can currently be purchased for approximately $22.83.

Merus has a market capitalization of $870.44 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

Merus employs 93 workers across the globe.

The official website for Merus is www.merus.nl.

Merus is headquartered at YALELAAN 62, UTRECHT P7, 3584 CM.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]